Acrivon therapeutics provides program updates and fourth quarter and full year 2024 financial results

Generative phosphoproteomics ap3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide sar delivering desirable pathway effects

ACRV Ratings Summary

ACRV Quant Ranking